Back

AIM secures Ampligen patent protection in Europe and UK through June 2041

Verifying
  • AIM ImmunoTech secured Ampligen patent protection for Long COVID across Europe and the United Kingdom.
  • Protection is expected through June 2041 after no opposition was filed by August 25, 2026.
  • The European coverage follows a newly issued U.S. patent involving Ampligen and pembrolizumab in cancer treatment.
The information on this website is generated using AI and we cannot guarantee its accuracy. Please use it as reference information only.